AbbVie Inc. (ABBV)

98.19
0.04 0.04
NYSE : Health Technology
Prev Close 98.22
Open 98.25
Day Low/High 96.42 / 98.67
52 Wk Low/High 69.47 / 125.86
Volume 2.78M
Avg Volume 8.08M
Exchange NYSE
Shares Outstanding 1.51B
Market Cap 147.57B
EPS 3.30
P/E Ratio 24.12
Div & Yield 3.84 (3.41%)

Latest News

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

More Than One Way to Win: Cramer's 'Mad Money' Recap (Thursday 8/9/18)

Jim Cramer says that in good markets there are always multiple ways for investors to win.

Biotechs: Adding to Radius Health, Flexion

Biotechs: Adding to Radius Health, Flexion

This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.

The 5 Highest-Yielding 'Dividend Aristocrats'

This exclusive group of stocks is among the best when it comes to returning cash to shareholders and building wealth over time.

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation Of AbbVie Inc. (ABBV)

NEW YORK, July 31, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of AbbVie Inc.

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

13 Lucky Blue Chip Stocks to Buy With the Market Looking Shaky

Blue Chip stocks are the way to go right now. Here are several key names worth considering.

AbbVie Reports Second-Quarter 2018 Financial Results

AbbVie Reports Second-Quarter 2018 Financial Results

- Reports Second-Quarter Diluted EPS of $1.26 on a GAAP Basis; Adjusted Diluted EPS of $2.00 Reflects Growth of 40.8 Percent

Amazon Could Rise Another 15% From Here: Market Recon

Amazon Could Rise Another 15% From Here: Market Recon

This stock is still going wild after earnings.

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

Amazon, Facebook, GDP, Intel and Exxon - 5 Things You Must Know

U.S. stock futures rise modestly on Friday ahead of data on second-quarter GDP; Amazon's profit in the second quarter tops $2 billion; Intel shares fell despite the chipmaker beating earnings forecasts.

Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc.

Keller Lenkner LLC Files Class Action Suit Against AbbVie Inc.

CHICAGO, July 26, 2018 /PRNewswire/ -- Keller Lenkner LLC ("Keller Lenkner") today announced that a class action has been commenced by an institutional investor on behalf of purchasers of AbbVie Inc.

3 'Strong Buy' Healthcare Stocks Poised to Surge

3 'Strong Buy' Healthcare Stocks Poised to Surge

Here are the top healthcare bets ticking all the boxes for analysts.

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

AbbVie Becomes #84 Most Shorted S&P 500 Component, Replacing XL Group

The most recent short interest data has been released for the 07/13/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

AbbVie Receives U.S. FDA Approval Of ORILISSA™ (elagolix) For The Management Of Moderate To Severe Pain Associated With Endometriosis

- ORILISSA™ (elagolix) is the first FDA-approved oral treatment for the management of moderate to severe pain associated with endometriosis in over a decade

How to Invest in Cannabis - In Its Many Forms

How to Invest in Cannabis - In Its Many Forms

As cannabis becomes more and more legal, investors have started to wonder what that means for them.

AbbVie Announces HUMIRA® (adalimumab) Patent License With Mylan

AbbVie Announces HUMIRA® (adalimumab) Patent License With Mylan

NORTH CHICAGO, Ill., July 17, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today patent license agreements with Mylan over its proposed biosimilar adalimumab product.

3 Pharma Stocks Goldman Sachs Sees as Buys

3 Pharma Stocks Goldman Sachs Sees as Buys

The large-cap pharma sector has left investors wanting more, but these three companies could provide some excitement at the end of the second quarter.

AbbVie Announces Submission Of Supplemental New Drug Application To US FDA For Venetoclax In Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

AbbVie Announces Submission Of Supplemental New Drug Application To US FDA For Venetoclax In Newly Diagnosed Acute Myeloid Leukemia Patients Ineligible For Intensive Chemotherapy

- Acute myeloid leukemia (AML) is one of the most aggressive cancers, with a very low survival rate and few options available for patients who are ineligible for intensive chemotherapy - Median survival is five to 10 months in older AML patients who are...

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) And Ongoing Ibrutinib Clinical Program

AbbVie Provides Update On Phase 3 Study Of Ibrutinib (IMBRUVICA®) In Blood Cancer Diffuse Large B-Cell Lymphoma (DLBCL) And Ongoing Ibrutinib Clinical Program

- The ibrutinib clinical program is designed to fully explore the potential of this first-in-class molecule as a single or combination therapy for multiple cancers and other diseases.

AbbVie To Host Second-Quarter 2018 Earnings Conference Call

AbbVie To Host Second-Quarter 2018 Earnings Conference Call

NORTH CHICAGO, Ill., July 10, 2018 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its second-quarter 2018 financial results on Friday, July 27, 2018, before the market opens.

10 Large-Cap Stocks With At Least 40% Upside Potential

10 Large-Cap Stocks With At Least 40% Upside Potential

On the search for promising stocks, give these 10 names from Goldman Sachs a consideration.

ABBV: Insiders Vs. Shorts

ABBV: Insiders Vs. Shorts

The most recent short interest data was recently released for the 06/15/2018 settlement date, and AbbVie Inc is the #146 most shorted of the S&P 500 components, based on 4.35 "days to cover." There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then divided by the average daily volume, to express the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Vertex Pharma Jumps 14% After Rival Releases Poor Cystic Fibrosis Drug Results

Galapagos' new cystic fibrosis drug trial results were weaker than expected.

What's the Difference Between Indica vs. Sativa?

What's the Difference Between Indica vs. Sativa?

Indica and sativa are commonly-known distinctions among cannabis enthusiasts. But is there actually a distinct difference between the two? What roles do cannabinoids and terpenes play?

AbbVie And Calico Announce Extension Of Groundbreaking Collaboration

AbbVie And Calico Announce Extension Of Groundbreaking Collaboration

- Extension builds on collaboration established in 2014

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted For Review By U.S. FDA With Potential To Broaden Treatment Use As A Combination Treatment Option With Rituximab In Waldenström's Macroglobulinemia (WM), A Rare Form Of Blood Cancer

IMBRUVICA® (ibrutinib) Supplemental New Drug Application Accepted For Review By U.S. FDA With Potential To Broaden Treatment Use As A Combination Treatment Option With Rituximab In Waldenström's Macroglobulinemia (WM), A Rare Form Of Blood Cancer

- The filing is based on data from the Phase 3 iNNOVATE study, which suggest that IMBRUVICA plus rituximab may improve outcomes across all lines of Waldenström's macroglobulinemia (WM) treatment, including patients with prior lines of therapy and various genetic factors, versus rituximab alone

AbbVie And Calibr Announce Collaboration For Next Generation T-cell Therapies

AbbVie And Calibr Announce Collaboration For Next Generation T-cell Therapies

- Collaboration will focus on switchable CAR-T therapies aimed primarily at solid tumors

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week Of Possibilities"

8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week Of Possibilities"

The Civic 50 recognizes AbbVie as one of the most community-minded companies in the U.S.

AbbVie Announces New Undetectable Minimal Residual Disease Data From Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial Of Venetoclax In Combination With Rituximab At 23rd European Hematology Association Annual Congress

AbbVie Announces New Undetectable Minimal Residual Disease Data From Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial Of Venetoclax In Combination With Rituximab At 23rd European Hematology Association Annual Congress

- 83 percent (n=100) of 121 patients who achieved undetectable minimal residual disease (uMRD) at the end of combination therapy with VenR (n=194), maintained uMRD and were progression-free at 13.8 months of follow-up[1]

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill., June 14, 2018 /PRNewswire/ -- The board of directors of AbbVie Inc.

TheStreet Quant Rating: B- (Buy)